Active	Status	Sponsor type	Region	Phase	Filter
26 Active 14 Inactive 40 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

26 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hoppe, Kara K
STAC-MyHEARTp, NCT05685251: Staying Healthy After Childbirth: My Hypertension Education and Reaching Target Program for Postpartum	Active, not recruiting	N/A	140	US	Health Coaching, Home Blood Pressure Monitoring	University of Wisconsin, Madison, UnityPoint Health-Meriter Foundation	Hypertension	04/25	04/25
NCT06689930: Dissemination and Implementation of a Community-driven Approach to Improve the Health of Women, Infants, and Families	Not yet recruiting	N/A	36	US	PDSA Cycles	University of Wisconsin, Madison, Centers for Disease Control and Prevention	Blood Pressure, Hypertension, Pregnancy Related, Health Equity	07/26	07/26
Pearce, Robert
IPOD-B3, NCT03124303: Interventions for Postoperative Delirium: Biomarker-3	Recruiting	N/A	470	US	High Density-Electroencephalogram, EEG, Magnetic Resonance Imaging, MRI, Blood specimen collection, Pupillometry	University of Wisconsin, Madison, National Institute on Aging (NIA)	Delirium	12/29	12/29
Liu, Yao
CSPC-JYL-PBSCT-02, NCT06026995: Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells	Recruiting	4	174	RoW	PEG-rhG-CSF, RhG-CSF	Chongqing University Cancer Hospital, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Lymphoma	01/24	06/24
NCT05786989: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma	Recruiting	4	32	RoW	selinexor, Selective Inhibitor of Nuclear, KPT-330	Chongqing University Cancer Hospital	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	03/24	09/24
SHINE-HF, NCT05583773: SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction	Recruiting	4	336	RoW	ShengXian-QuYu Decoction, Placebo	China-Japan Friendship Hospital	Heart Failure	08/25	12/25
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Active, not recruiting	3	440	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma	Not yet recruiting	2	77	RoW	Orelabrutinib and Gemox, O-Gemox	Sun Yat-sen University	DLBCL	12/23	12/25
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma	Completed	2	178	RoW	HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor	Hutchison Medipharma Limited	Marginal Zone Lymphoma, Follicular Lymphoma	02/24	02/24
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Recruiting	1/2	39	RoW	400mg of TQB3909 tablets, 600mg of TQB3909 tablets	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Mantle Cell Lymphoma	12/24	12/24
ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma	Recruiting	1/2	112	RoW	Prizloncabtagene autoleucel, C-CAR039	Shanghai AbelZeta Ltd.	Relapsed/Refractory Large B-Cell Lymphoma	10/25	12/27
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL	Recruiting	N/A	200	RoW	Relmacabtagene Autoleucel, JWCAR029	Shanghai Ming Ju Biotechnology Co., Ltd.	Large B-cell Lymphoma	12/24	12/24
NCT06060080: Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma	Recruiting	N/A	7	RoW	pegylated recombinant human granulocyte-colony stimulating factor, PEG-rhG-CSF	Yao Liu	Lymphoma, Multiple Myeloma	12/23	04/24
NCT05401175: Hematopoietic Stem Cell-containing Autologous Blood Transfusion for Bone Marrow Protection in Patients With Cervical Cancer	Recruiting	N/A	40	RoW	Autologous blood transfusion with haematopoietic stem cells	Chongqing University Cancer Hospital	Cervical Cancer	04/25	04/27
NCT05401162: Chemotherapy Supported by Autologous Hematopoietic Stem Cells	Recruiting	N/A	40	RoW	Autologous blood transfusion with haematopoietic stem cells	Chongqing University Cancer Hospital	Ovarian Cancer	05/25	05/27
NCT06257082: Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities	Not yet recruiting	N/A	1526	US	Online Survey	University of Wisconsin, Madison, National Eye Institute (NEI)	Diabetic Retinopathy	05/26	05/26
NCT05254535: I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study	Enrolling by invitation	N/A	10	US	I-SITE, Implementation for Sustained Impact in Teleophthalmology	University of Wisconsin, Madison, National Eye Institute (NEI)	Diabetic Retinopathy	12/26	01/27
NCT05773495: Implementation of Teleophthalmology in Urban Health Systems Study	Enrolling by invitation	N/A	2000	US	I-SITE Intervention, Usual Care Teleophthalmology	University of Wisconsin, Madison, National Eye Institute (NEI)	Diabetic Retinopathy	11/26	11/26
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial	Recruiting	N/A	790	Europe, Canada, US	Low Energy SLT, Standard Energy SLT	West Virginia University, University of Pittsburgh	Glaucoma and Ocular Hypertension	06/27	08/27
Parajuli, Sandesh
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients	Recruiting	3	90	US	Letermovir, Prevymis	University of Wisconsin, Madison, Merck Sharp & Dohme LLC	Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant	09/26	09/26
NCT03950414: A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients	Terminated	1	2	US	CMV specific T-cells	University of Wisconsin, Madison	Cytomegalovirus Infections, Solid Organ Transplant	07/22	07/22
NCT05042076: BK With VST for Kidney Transplant Patients	Completed	1	3	US	BK-specific T cells from Donor Lymphocytes	University of Wisconsin, Madison	Kidney Transplant Infection, BK Virus Infection	05/24	05/24
Berian, Julia R
NCT06184919: Preparing Older Adults for Major Surgery With Preoperative Comprehensive Geriatric Assessments	Enrolling by invitation	N/A	160	US	Process Mapping: Observations, Process Mapping: Interviews, Process Mapping: Focus Group, Participatory Design	University of Wisconsin, Madison, National Institute on Aging (NIA)	Surgery, Aging, Health Care Utilization, Frailty	12/24	04/28
NCT06184724: Implementation Pilot of Preoperative CGA Before Major Surgery	Not yet recruiting	N/A	40	US	Implementation Package for CGA, Routine Clinical Care	University of Wisconsin, Madison, National Institute on Aging (NIA)	Surgery, Geriatric Assessment, Health Services Research, Implementation Science	04/28	04/29
Jorgenson, Margaret
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients	Recruiting	3	90	US	Letermovir, Prevymis	University of Wisconsin, Madison, Merck Sharp & Dohme LLC	Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant	09/26	09/26
Westergaard, Sara
PHP Team, NCT06581224: Implementation of a Primary Hospital Provider (PHP) Team	Recruiting	N/A	700	US	Primary Hospital Provider Team	University of Wisconsin, Madison	High-need, High-complexity	10/25	11/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hoppe, Kara K
STAC-MyHEARTp, NCT05685251: Staying Healthy After Childbirth: My Hypertension Education and Reaching Target Program for Postpartum	Active, not recruiting	N/A	140	US	Health Coaching, Home Blood Pressure Monitoring	University of Wisconsin, Madison, UnityPoint Health-Meriter Foundation	Hypertension	04/25	04/25
NCT06689930: Dissemination and Implementation of a Community-driven Approach to Improve the Health of Women, Infants, and Families	Not yet recruiting	N/A	36	US	PDSA Cycles	University of Wisconsin, Madison, Centers for Disease Control and Prevention	Blood Pressure, Hypertension, Pregnancy Related, Health Equity	07/26	07/26
Pearce, Robert
IPOD-B3, NCT03124303: Interventions for Postoperative Delirium: Biomarker-3	Recruiting	N/A	470	US	High Density-Electroencephalogram, EEG, Magnetic Resonance Imaging, MRI, Blood specimen collection, Pupillometry	University of Wisconsin, Madison, National Institute on Aging (NIA)	Delirium	12/29	12/29
Liu, Yao
CSPC-JYL-PBSCT-02, NCT06026995: Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells	Recruiting	4	174	RoW	PEG-rhG-CSF, RhG-CSF	Chongqing University Cancer Hospital, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Lymphoma	01/24	06/24
NCT05786989: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma	Recruiting	4	32	RoW	selinexor, Selective Inhibitor of Nuclear, KPT-330	Chongqing University Cancer Hospital	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	03/24	09/24
SHINE-HF, NCT05583773: SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction	Recruiting	4	336	RoW	ShengXian-QuYu Decoction, Placebo	China-Japan Friendship Hospital	Heart Failure	08/25	12/25
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Active, not recruiting	3	440	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma	Not yet recruiting	2	77	RoW	Orelabrutinib and Gemox, O-Gemox	Sun Yat-sen University	DLBCL	12/23	12/25
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma	Completed	2	178	RoW	HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor	Hutchison Medipharma Limited	Marginal Zone Lymphoma, Follicular Lymphoma	02/24	02/24
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Recruiting	1/2	39	RoW	400mg of TQB3909 tablets, 600mg of TQB3909 tablets	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Mantle Cell Lymphoma	12/24	12/24
ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma	Recruiting	1/2	112	RoW	Prizloncabtagene autoleucel, C-CAR039	Shanghai AbelZeta Ltd.	Relapsed/Refractory Large B-Cell Lymphoma	10/25	12/27
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL	Recruiting	N/A	200	RoW	Relmacabtagene Autoleucel, JWCAR029	Shanghai Ming Ju Biotechnology Co., Ltd.	Large B-cell Lymphoma	12/24	12/24
NCT06060080: Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma	Recruiting	N/A	7	RoW	pegylated recombinant human granulocyte-colony stimulating factor, PEG-rhG-CSF	Yao Liu	Lymphoma, Multiple Myeloma	12/23	04/24
NCT05401175: Hematopoietic Stem Cell-containing Autologous Blood Transfusion for Bone Marrow Protection in Patients With Cervical Cancer	Recruiting	N/A	40	RoW	Autologous blood transfusion with haematopoietic stem cells	Chongqing University Cancer Hospital	Cervical Cancer	04/25	04/27
NCT05401162: Chemotherapy Supported by Autologous Hematopoietic Stem Cells	Recruiting	N/A	40	RoW	Autologous blood transfusion with haematopoietic stem cells	Chongqing University Cancer Hospital	Ovarian Cancer	05/25	05/27
NCT06257082: Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities	Not yet recruiting	N/A	1526	US	Online Survey	University of Wisconsin, Madison, National Eye Institute (NEI)	Diabetic Retinopathy	05/26	05/26
NCT05254535: I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study	Enrolling by invitation	N/A	10	US	I-SITE, Implementation for Sustained Impact in Teleophthalmology	University of Wisconsin, Madison, National Eye Institute (NEI)	Diabetic Retinopathy	12/26	01/27
NCT05773495: Implementation of Teleophthalmology in Urban Health Systems Study	Enrolling by invitation	N/A	2000	US	I-SITE Intervention, Usual Care Teleophthalmology	University of Wisconsin, Madison, National Eye Institute (NEI)	Diabetic Retinopathy	11/26	11/26
COAST, NCT04967989: Clarifying the Optimal Application of SLT Therapy Trial	Recruiting	N/A	790	Europe, Canada, US	Low Energy SLT, Standard Energy SLT	West Virginia University, University of Pittsburgh	Glaucoma and Ocular Hypertension	06/27	08/27
Parajuli, Sandesh
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients	Recruiting	3	90	US	Letermovir, Prevymis	University of Wisconsin, Madison, Merck Sharp & Dohme LLC	Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant	09/26	09/26
NCT03950414: A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients	Terminated	1	2	US	CMV specific T-cells	University of Wisconsin, Madison	Cytomegalovirus Infections, Solid Organ Transplant	07/22	07/22
NCT05042076: BK With VST for Kidney Transplant Patients	Completed	1	3	US	BK-specific T cells from Donor Lymphocytes	University of Wisconsin, Madison	Kidney Transplant Infection, BK Virus Infection	05/24	05/24
Berian, Julia R
NCT06184919: Preparing Older Adults for Major Surgery With Preoperative Comprehensive Geriatric Assessments	Enrolling by invitation	N/A	160	US	Process Mapping: Observations, Process Mapping: Interviews, Process Mapping: Focus Group, Participatory Design	University of Wisconsin, Madison, National Institute on Aging (NIA)	Surgery, Aging, Health Care Utilization, Frailty	12/24	04/28
NCT06184724: Implementation Pilot of Preoperative CGA Before Major Surgery	Not yet recruiting	N/A	40	US	Implementation Package for CGA, Routine Clinical Care	University of Wisconsin, Madison, National Institute on Aging (NIA)	Surgery, Geriatric Assessment, Health Services Research, Implementation Science	04/28	04/29
Jorgenson, Margaret
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients	Recruiting	3	90	US	Letermovir, Prevymis	University of Wisconsin, Madison, Merck Sharp & Dohme LLC	Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant	09/26	09/26
Westergaard, Sara
PHP Team, NCT06581224: Implementation of a Primary Hospital Provider (PHP) Team	Recruiting	N/A	700	US	Primary Hospital Provider Team	University of Wisconsin, Madison	High-need, High-complexity	10/25	11/25